{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:51:05Z","timestamp":1791305465618,"version":"4.3.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s11095-026-04159-4","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:00:25Z","timestamp":1788210025000},"page":"3083-3104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Generic Long-Acting Injectable Product Availability and Approval Standards"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7249-8344","authenticated-orcid":false,"given":"Krista","family":"Anim Anno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5871-1950","authenticated-orcid":false,"given":"Doortje Esther","family":"Lubberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0639-3162","authenticated-orcid":false,"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8264-2452","authenticated-orcid":false,"given":"Sarah","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7884-923X","authenticated-orcid":false,"given":"Jessica T.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7165-4579","authenticated-orcid":false,"given":"Kevin","family":"Blake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3590-0584","authenticated-orcid":false,"given":"Arno","family":"Nolting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6030-4271","authenticated-orcid":false,"given":"Carolien","family":"Versantvoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3876-638X","authenticated-orcid":false,"given":"Wenlei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"4159_CR1","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jconrel.2021.06.017","volume":"336","author":"MN O\u2019Brien","year":"2021","unstructured":"O\u2019Brien MN, Jiang W, Wang Y, Loffredo DM. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release. 2021;336:144\u201358.","journal-title":"J Control Release"},{"key":"4159_CR2","unstructured":"U.S. Food and Drug Administration. Drugs@FDA: FDA-approved drugs [Internet]. FDA; [cited 2026 Jul 30]. Available\u00a0from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"key":"4159_CR3","unstructured":"Brill A. Potential savings from accelerating US approval of complex generics [Internet]. 2021 [cited 2026 Jul 30]. Available from: https:\/\/accessiblemeds.org\/wp-content\/uploads\/2024\/12\/Potential-Savings-Complex-Generics-Feb2021.pdf."},{"key":"4159_CR4","unstructured":"U.S. Food and Drug Administration. Classifying approved new drug products and drug-device combination products as complex products for generic drug development purposes. MAPP 5240.10. FDA, Office of Generic Drugs; 2022."},{"key":"4159_CR5","doi-asserted-by":"crossref","unstructured":"Andrea B, Philippe B, Sudhir SC, Sayantan C, Ashish G, Betty G, et al. Current state and opportunities with long-acting injectables: industry perspectives from the Innovation and Quality Consortium \u201clong-acting injectables\u201d working group. Pharm Res. 2023;40(7):1601\u201331.","DOI":"10.1007\/s11095-022-03391-y"},{"key":"4159_CR6","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) [Internet]. Available from: https:\/\/www.ich.org\/. Accessed 1 Aug 2024."},{"key":"4159_CR7","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Reflection paper further opportunities for harmonization of standards for generic drugs. 2018. Available from: https:\/\/admin.ich.org\/sites\/default\/files\/2019-04\/ICH_ReflectionPaper_GenericDrugs_Final_2019_0130.pdf. Accessed 2 Mar 2026."},{"key":"4159_CR8","unstructured":"College ter Beoordeling Geneesmiddelen - Medicines Evaluation Board (CBG-MEB). MEB Annual report 2023: Opportunities for tomorrow. Utrecht, 2023.  [cited 2024 Apr 18]. Available from: https:\/\/www.cbg-meb.nl\/site\/binaries\/site-content\/collections\/documents\/2023\/01\/01\/cbg-jaarverslag-2023-kansen-voor-morgen\/240418-MEB+Annual+report+2023_EN.pdf."},{"key":"4159_CR9","unstructured":"College ter Beoordeling Geneesmiddelen - Medicines Evaluation Board (CBG-MEB). Geneesmiddeleninformatiebank. Available from: https:\/\/www.geneesmiddeleninformatiebank.nl\/.\u00a0Accessed 18 Feb 2026."},{"key":"4159_CR10","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte - Federal Institute for Drugs and Medical Devices. Arzneimittel-Informationssystem. Available from: https:\/\/portal.dimdi.de\/amguifree\/am\/search.xhtml. Accessed 17 May 2023."},{"key":"4159_CR11","unstructured":"La Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios - The Spanish Agency of Medicines and Medical Devices. Centro de informaci\u00f3n de medicamentos (CIMA). Available from: http:\/\/cima.aemps.es\/cima\/publico\/home.html. Accessed 31 May 2023."},{"key":"4159_CR12","unstructured":"Swissmedic. Lists and directories. 1.1 Human Medicines: Authorised human medicinal products.\u00a0[cited 2026 Mar 02]. Available from: https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/services\/listen_neu.html#319575900."},{"key":"4159_CR13","unstructured":"European Medicines Agency Coordination Group for Mutual Recognition and Decentralised Procedures - Human. MRI Product Index. Available from: https:\/\/mri.cts-mrp.eu\/portal\/home?domain=h.\u00a0Accessed 4 Aug 2023."},{"key":"4159_CR14","unstructured":"U.S. Food and Drug Administration. Product-specific guidances for generic drug development [Internet]. [cited 2026 Jul 31]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/psg\/index.cfm."},{"key":"4159_CR15","unstructured":"European Medicines Agency (EMA). Product-specific bioequivalence guidance [Internet]. EMA; [cited 2026 Jul 31]. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/scientific-guidelines\/clinical-pharmacology-pharmacokinetics-guidelines\/product-specific-bioequivalence-guidance."},{"key":"4159_CR16","unstructured":"European Medicine Agency Committee for Medicinal Products for Human Use. Guideline on the pharmacokinetics and clinical evaluation of modified release dosage forms. 2014. Available from https:\/\/www.ema.europa.eu\/en\/pharmacokinetic-clinical-evaluation-modified-release-dosage-forms-scientific-guideline. Accessed 30 Jul 2026."},{"key":"4159_CR17","unstructured":"European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP). Guideline on the Investigation of Bioequivalence. 2010."},{"key":"4159_CR18","unstructured":"European Parliament, Council of the European Union (EU). VOLUME 2A Procedures for marketing authorisation CHAPTER 1 MARKETING AUTHORISATION. 2019."},{"key":"4159_CR19","unstructured":"European Medicines Agency (EMA). Authorisation of medicines | European Medicines Agency. Available from: https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do\/authorisation-medicines.\u00a0Accessed 7 Jul 2023."},{"key":"4159_CR20","unstructured":"European Medicines Agency (EMA) Committee for Medicinal Product for Human Use (CHMP). Rules of Procedure. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/chmp-rules-procedure_en.pdf.\u00a0Accessed 16 Aug 2023."},{"key":"4159_CR21","unstructured":"Swissmedic. Authorisation of human medicinal product with new active substance Identification number. 2024. Available from: https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/information\/anpassung-wl-ham-nas.html.\u00a0Accessed 30 June 2023."},{"key":"4159_CR22","unstructured":"Swiss federal authorities. SR 812.21 - Federal Act on Medicinal Products and Medical Devices (Therapeutic Products Act, TPA). Fedlex. 2000. Available from: https:\/\/www.fedlex.admin.ch\/eli\/cc\/2001\/422\/en.\u00a0Accessed 2 Mar 2026."},{"key":"4159_CR23","unstructured":"Swissmedic. Authorisation of human medicinal product with known active substance Identification number. 2024. Available from: https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/humanarzneimittel\/authorisations\/information\/anpassung-wl-bws.html.\u00a0Accessed 30 June 2023."},{"issue":"3","key":"4159_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1208\/s12248-022-00695-0","volume":"24","author":"JC Shah","year":"2022","unstructured":"Shah JC, Hong J.\u00a0Model for long acting injectables (depot formulation) based on pharmacokinetics and\u00a0physical chemical properties. AAPS J. 2022;24(3):44.","journal-title":"AAPS J"},{"key":"4159_CR25","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Assessment report Faslodex | Procedure No. EMEA\/H\/C\/000540. 2005. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/faslodex-epar-public-assessment-report_en.pdf.\u00a0Accessed 14 Aug 2023."},{"key":"4159_CR26","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Assessment report Fulvestrant Mylan | Procedure No. EMEA\/H\/C\/004649\/0000. 2017. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/fulvestrant-mylan-epar-public-assessment-report_en.pdf.\u00a0Accessed 14 Aug 2023."},{"key":"4159_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.addr.2020.11.008","volume":"167","author":"N Christian Isalomboto","year":"2020","unstructured":"Christian Isalomboto N, Andreas F, Mazda R-M, Marieta Duvnjak R, Birgit K, Thomas U, et al. Clinically established biodegradable long acting injectables: An industry perspective. Adv Drug Deliv Rev. 2020;167:19\u201346.","journal-title":"Adv Drug Deliv Rev"},{"key":"4159_CR28","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Assessment report Camcevi | Procedure No. EMEA\/H\/C\/005034\/0000. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/camcevi-epar-public-assessment-report_en.pdf.\u00a0Accessed 14 Aug 2023."},{"key":"4159_CR29","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Assessment report Xeplion | Procedure No. EMEA\/H\/C\/2105. 2011. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/xeplion-epar-public-assessment-report_en.pdf. Accessed 14 Aug 2023."},{"key":"4159_CR30","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Assessment report Paliperidone Janssen-Cilag International | Procedure No. EMEA\/H\/C\/005486\/0000. 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/paliperidone-janssen-epar-public-assessment-report_en.pdf. Accessed 15 Aug 2023."},{"key":"4159_CR31","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Assessment report Zypadhera | Procedure No. EMEA\/H\/C\/000890. 2008. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/zypadhera-epar-public-assessment-report_en.pdf. Accessed 14 Aug 2023."},{"key":"4159_CR32","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Assessment report Abilify Maintena | Procedure No. EMEA\/H\/C\/002755\/0000. 2013. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/abilify-maintena-epar-public-assessment-report_en.pdf. Accessed 14 Aug 2023."},{"key":"4159_CR33","unstructured":"U.S. Food and Drug Administration. Lupaneta pack (leuprolide acetate for depot suspension, for injection; norethindrone acetate tablets), co-packaged for intramuscular use and for oral use, respectively [prescribing information]. FDA; 2023 [cited 2026 Aug 10]. Available from:\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/203696s005s006lbl.pdf."},{"key":"4159_CR34","unstructured":"U.S. Food and Drug Administration. Zynrelef (bupivacaine and meloxicam) extended-release solution, for instillation use [prescribing information]. FDA; 2025 [cited 2026 Aug 10]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/211988Orig1s021lbl.pdf."},{"key":"4159_CR35","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Assessment report Exparel liposomal | Procedure No. EMEA\/H\/C\/004586\/0000. 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/exparel-liposomal-epar-public-assessment-report_en.pdf. Accessed 18 Aug 2023."},{"key":"4159_CR36","unstructured":"U.S. Food and Drug Administration. Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended-release injectable suspension), co-packaged for intramuscular use [prescribing information]. FDA; 2025 [cited 2026 Aug 10]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/212888Orig1s017lbl.pdf."},{"key":"4159_CR37","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jconrel.2020.05.022","volume":"324","author":"DH Surve","year":"2020","unstructured":"Surve DH, Jindal AB. Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs. J Control Release. 2020;324:379\u2013404.","journal-title":"J Control Release"},{"issue":"9","key":"4159_CR38","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/17425247.2020.1783233","volume":"17","author":"DA Cobb","year":"2020","unstructured":"Cobb DA, Smith NA, Edagwa BJ, McMillan JEM. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. Expert Opin Drug Deliv. 2020;17(9):1227\u201338.","journal-title":"Expert Opin Drug Deliv"},{"key":"4159_CR39","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Assessment report Vocabria | Procedure No. EMEA\/H\/C\/004976\/0000. 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/vocabria-epar-public-assessment-report_en.pdf. Accessed 14 Aug 2023."},{"key":"4159_CR40","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Assessment report Rekambys | Procedure No. EMEA\/H\/C\/005060\/0000. 2020. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/rekambys-epar-public-assessment-report_en.pdf. Accessed 14 Aug 2023."},{"issue":"5","key":"4159_CR41","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1002\/cpt.70238","volume":"119","author":"U Arshad","year":"2026","unstructured":"Arshad U, Gaayeb L, Pertinez H, Rajoli RKR, Watkins M, Nimbolkar P, et al. Accelerating generic long-acting antiretrovirals for global HIV treatment: workshop findings and a roadmap to access. Clin Pharmacol Ther. 2026;119(5):1195\u2013204.","journal-title":"Clin Pharmacol Ther"},{"key":"4159_CR42","unstructured":"U.S. Food and Drug Administration. Remarks by Commissioner Califf to the Advancing Generic Drug Development: Translating Science to Approval Workshop 2023 [Internet]. [cited 2026 Jul 31]. Available from: https:\/\/www.youtube.com\/watch?v=u-mAAZI9Eb4. Accessed 31 Jul 2026."},{"key":"4159_CR43","unstructured":"Drugs.com. Generic Risperdal Consta availability [Internet]. Drugs.com; [cited 2026 Aug 3]. Available from: https:\/\/www.drugs.com\/availability\/generic-risperdal-consta.html."},{"key":"4159_CR44","unstructured":"Teva Pharmaceuticals. Teva offers the first FDA-approved generic version of Sandostatin\u00ae LAR Depot [Internet]. Teva Pharmaceuticals; [cited 2026 Aug 3]. Available from: https:\/\/www.tevaoctreotide.com\/."},{"key":"4159_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26051247","author":"Y Hua","year":"2021","unstructured":"Hua Y, Wang Z, Wang D, Lin X, Liu B, Zhang H, et al. Key factor study for generic long-acting PLGA microspheres based on a reverse engineering of Vivitrol\u00ae. Molecules. 2021. https:\/\/doi.org\/10.3390\/molecules26051247.","journal-title":"Molecules"},{"issue":"10","key":"4159_CR46","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1586\/14737175.7.10.1265","volume":"7","author":"P Mannelli","year":"2007","unstructured":"Mannelli P, Peindl K, Masand PS, Patkar AA. Long-acting injectable naltrexone for the treatment of alcohol dependence. Expert Rev Neurother. 2007;7(10):1265\u201377.","journal-title":"Expert Rev Neurother"},{"issue":"5","key":"4159_CR47","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/2045125314540297","volume":"4","author":"S Brissos","year":"2014","unstructured":"Brissos S, Veguilla MR, Taylor D, Balanza-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198\u2013219.","journal-title":"Ther Adv Psychopharmacol"},{"key":"#cr-split#-4159_CR48.1","unstructured":"U.S. Food and Drug Administration. 2024 first generic drug approvals [Internet]. FDA"},{"key":"#cr-split#-4159_CR48.2","unstructured":"2025 Oct 23 [cited 2026 Aug 3]. Available from: https:\/\/www.fda.gov\/drugs\/drug-and-biologic-approval-and-ind-activity-reports\/2024-first-generic-drug-approvals."},{"issue":"18","key":"4159_CR49","doi-asserted-by":"publisher","first-page":"10258","DOI":"10.1073\/pnas.1730609100","volume":"100","author":"C Val\u00e9ry","year":"2003","unstructured":"Val\u00e9ry C, Paternostre M, Robert B, Gulik-Krzywicki T, Narayanan T, Dedieu JC, et al. Biomimetic organization: octapeptide self-assembly into nanotubes of viral capsid-like dimension. Proc Natl Acad Sci U S A. 2003;100(18):10258\u201362.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"4159_CR50","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s12029-016-9866-9","volume":"47","author":"EM Wolin","year":"2016","unstructured":"Wolin EM, Manon A, Chassaing C, Lewis A, Bertocchi L, Richard J, et al. Lanreotide depot: an antineoplastic treatment of carcinoid or neuroendocrine tumors. J Gastrointest Cancer. 2016;47(4):366\u201374.","journal-title":"J Gastrointest Cancer"},{"key":"4159_CR51","unstructured":"U.S. Food and Drug Administration. FDA commissioner and chief scientist announce decision to withdraw approval of Makena [Internet]. FDA; 2023 Apr 6 [cited 2026 Aug 3]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-commissioner-and-chief-scientist-announce-decision-withdraw-approval-makena."},{"key":"4159_CR52","unstructured":"European Medicines Agency (EMA). Public statement DepoCyte: Withdrawal of the marketing authorisation in the European Union. 2019. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/public-statement-depocyte-withdrawal-marketing-authorisation-european-union_en.pdf. Accessed 16 Aug 2023."},{"key":"4159_CR53","unstructured":"U.S. Securities and Exchange Commission (SEC). DepoCyt(e) Discontinuation. 2017. Available from: https:\/\/www.sec.gov\/Archives\/edgar\/data\/1396814\/000139681418000009\/R22.htm. Accessed 2 Mar 2026."},{"key":"4159_CR54","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Lanreotide acetate, prolonged-release solution for injection in prefilled syringe 60, 90 and 120 mg product-specific bioequivalence guidance. 2022. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/lanreotide-acetate-prolonged-release-solution-injection-prefilled-syringe-60-90-and-120-mg-productspecific-bioequivalence-guidance_en.pdf. Accessed 6 Sept 2023."},{"key":"4159_CR55","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Paliperidone palmitate depot suspension for injection 25 mg, 50 mg, 75 mg, 100 mg and 150 mg product-specific bioequivalence guidance. 2017. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/paliperidone-palmitate-depot-suspension-injection-25-mg-50-mg-75-mg-100-mg-and-150-mg-product-specific-bioequivalence-guidance_en.pdf. Accessed 6 Sept 2023."},{"key":"4159_CR56","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Octreotide acetate depot powder and solvent for suspension for injection 10 mg, 20 mg and 30 mg product-specific bioequivalence guidance. 2019. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/octreotide-acetate-depot-powder-and-solvent-suspension-injection-10-mg-20-mg-and-30-mg-product-specific-bioequivalence-guidance_en.pdf. Accessed 6 Sept 2023."},{"key":"4159_CR57","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Exenatide powder and solvent for prolonged-release suspension for injection, 2 mg, and powder and solvent for prolonged-release suspension for injection in pre-filled pen, 2 mg product-specific bioequivalence guidance. 2017. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/exenatide-powder-and-solvent-prolonged-release-suspension-injection-2-mg-and-powder-and-solvent-prolonged-release-suspension-injection-pre-filled-pen-2-mg-product-specific-bioequivalence-guidance_en.pdf. Accessed 6 Sept 2023."},{"key":"4159_CR58","unstructured":"U.S. Food and Drug Administration. Invega sustenna (paliperidone palmitate) extended-release injectable suspension [prescribing information]. FDA; 2009 [cited 2026 Aug 10]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022264lbl.pdf."},{"key":"4159_CR59","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Paliperidone palmitate depot suspension for injection (every 3 months) 175, 263, 350 and 525 mg product-specific bioequivalence guidance. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/paliperidone-palmitate-depot-suspension-injection-every-3-months-175-263-350-525-mg-product-specific-bioequivalence-guidance_en.pdf-0. Accessed 2 Mar 2026."},{"key":"4159_CR60","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Assessment report Buvidal | Procedure No. EMEA\/H\/C\/004651\/0000. 2018. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/buvidal-epar-public-assessment-report_en.pdf. Accessed 14 Aug 2023."},{"key":"4159_CR61","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Assessment report Okedi | Procedure No. EMEA\/H\/C\/005406\/0000. 2021. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/okedi-epar-public-assessment-report_en.pdf. Accessed 14 Aug 2023."},{"key":"4159_CR62","doi-asserted-by":"publisher","unstructured":"Lim YW, Tan WS, Ho KL, Mariatulqabtiah AR, Abu Kasim NH, Abd Rahman N, et al. Challenges and complications of poly(lactic-co-glycolic acid)-based long-acting drug product development. Pharmaceutics. 2022. https:\/\/doi.org\/10.3390\/pharmaceutics14030614.","DOI":"10.3390\/pharmaceutics14030614"},{"issue":"4","key":"4159_CR63","doi-asserted-by":"publisher","first-page":"8","DOI":"10.14227\/DT250418P8","volume":"25","author":"V Gray","year":"2018","unstructured":"Gray V, Cady S, Curran D, DeMuth J, Eradiri O, Hussain M, et al. In vitro release test methods for drug formulations for parenteral applications. Dissolut Technol. 2018;25(4):8\u201313.","journal-title":"Dissolut Technol"},{"key":"4159_CR64","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jconrel.2024.11.021","volume":"377","author":"Y Wang","year":"2025","unstructured":"Wang Y, Otte A, Park H, Park K. In vitro-in vivo correlation (IVIVC) development for long-acting injectable drug products based on poly(lactide-co-glycolide). J Control Release. 2025;377:186\u201396.","journal-title":"J Control Release"},{"key":"4159_CR65","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (EMA CHMP). Assessment report Sixmo | Procedure No. EMEA\/H\/C\/004743\/0000. 2019. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/sixmo-epar-public-assessment-report_en.pdf. Accessed 14 Aug 2023."},{"key":"4159_CR66","unstructured":"U.S. Food and Drug Administration. Generic drug cluster \u2013 one-year progress report [Internet]. FDA; 2022 Jul 28 [cited 2026 Aug 3]. Available from: https:\/\/www.fda.gov\/drugs\/generic-drugs\/generic-drug-cluster-one-year-progress-report."},{"key":"4159_CR67","unstructured":"U.S. Food and Drug Administration. Global generic drug affairs [Internet]. FDA; 2025 Dec 1 [cited 2026 Aug 3]. Available from: https:\/\/www.fda.gov\/drugs\/generic-drugs\/global-generic-drug-affairs."},{"key":"#cr-split#-4159_CR68.1","unstructured":"U.S. Food and Drug Administration. Advancing generic drug development: translating science to approval 2023 [Internet]. FDA"},{"key":"#cr-split#-4159_CR68.2","unstructured":"2023 Oct 27 [cited 2026 Aug 3]. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/advancing-generic-drug-development-translating-science-approval-2023-09132023."},{"key":"4159_CR69","unstructured":"U.S. Food and Drug Administration. FDA-EMA parallel scientific advice pilot program for complex generic\/hybrid products [Internet]. FDA; 2022 Oct 18 [cited 2026 Aug 3]. Available from: https:\/\/www.fda.gov\/drugs\/generic-drugs\/fda-ema-parallel-scientific-advice-pilot-program-complex-generichybrid-products."},{"key":"4159_CR70","unstructured":"Insights About the FDA\/EMA Parallel Scientific Advice Program for Complex Generic\/Hybrid Drug Products. Available from: https:\/\/www.fda.gov\/drugs\/cder-small-business-industry-assistance-sbia\/audio-transcript-insights-about-fdaema-parallel-scientific-advice-program-complex-generichybrid-drug. Accessed 30 Jul 2026."},{"key":"4159_CR71","unstructured":"U.S. Food and Drug Administration. FY2023 GDUFA science and research report. FDA; 2023 [cited 2026 Aug 10]. Available from: https:\/\/www.fda.gov\/drugs\/generic-drugs\/generic-drug-research-related-guidances-reports."},{"issue":"4","key":"4159_CR72","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1208\/s12248-021-00611-y","volume":"23","author":"Y Wang","year":"2021","unstructured":"Wang Y, Qin B, Xia G, Choi SH. FDA\u2019s poly (lactic-co-glycolic acid) research program and regulatory outcomes. AAPS J. 2021;23(4):92.","journal-title":"AAPS J"},{"key":"4159_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2023.122642","volume":"634","author":"Q Bao","year":"2023","unstructured":"Bao Q, Wang X, Wan B, Zou Y, Wang Y, Burgess DJ. Development of in vitro-in vivo correlations for long-acting injectable suspensions. Int J Pharm. 2023;634:122642.","journal-title":"Int J Pharm"},{"key":"4159_CR74","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jconrel.2024.09.045","volume":"375","author":"X Lin","year":"2024","unstructured":"Lin X, Al Zouabi NN, Ward LE, Zhen Z, Darji M, Masese FK, et al. Implant dynamics, inner structure, and their impact on drug release of in situ forming implants uncovered through CT imaging. J Control Release. 2024;375:802\u201311.","journal-title":"J Control Release"},{"issue":"1","key":"4159_CR75","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1021\/acs.molpharmaceut.4c01057","volume":"22","author":"J Garner","year":"2025","unstructured":"Garner J, Skidmore S, Overdorf G, Hadar J, Park H, Park K, et al. A new analytical method for quantifying acid-end-cap PLGA in sub-milligram quantities. Mol Pharm. 2025;22(1):446\u201358.","journal-title":"Mol Pharm"},{"key":"4159_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125512","volume":"675","author":"AG Clark","year":"2025","unstructured":"Clark AG, Wong J, Wang R, Wang Y, Qin B, Burgess DJ, et al. Aging-induced microstructural evolution in risperidone loaded PLGA microspheres. Int J Pharm. 2025;675:125512.","journal-title":"Int J Pharm"},{"key":"4159_CR77","unstructured":"Center for Research on Complex Generics (CRCG). Education & training [Internet]. [cited 2026 Aug 3]. Available from: https:\/\/www.complexgenerics.org\/education-training\/."},{"issue":"2","key":"4159_CR78","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.70170","volume":"15","author":"DE Lubberts","year":"2026","unstructured":"Lubberts DE, Eleveld DJ, Verscheijden LFM, Colin PJ, Koomen JV. Evaluating Model-Based Extrapolation of Plasma Exposure for Long-Acting Injectable Products: From Single- to Multiple-Dose Trials. CPT Pharmacometrics Syst Pharmacol. 2026;15(2):e70170.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"4159_CR79","unstructured":"College ter Beoordeling Geneesmiddelen - Medicines Evaluation Board (CBG-MEB). Towards Tomorrow: A status update on the Medicines Evaluation Board Science Policy 2020-2024. 2023. Available from: https:\/\/www.cbg-meb.nl\/site\/binaries\/site-content\/collections\/documents\/2023\/04\/13\/wetenschapsbrochure---towards-tomorrow\/230413-Science+Brochure-Towards-Tomorrow.pdf. Accessed 2 Mar 2026."}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04159-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11095-026-04159-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-026-04159-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:54:52Z","timestamp":1791302092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11095-026-04159-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":81,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["4159"],"URL":"https:\/\/doi.org\/10.1007\/s11095-026-04159-4","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated to include ORCIDs.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared no competing interests for this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agencies or other organizations with which the authors are affiliated.","order":2,"name":"Ethics","label":"Disclaimers","group":{"name":"EthicsHeading","label":"Declarations"}}]}}